Oncology nurse Diane Stanaway offers essential sun protection strategies as NJ prepares for the heat of the 2026 World Cup and rising skin cancer rates. As MetLife Stadium in East Rutherford, New ...
ASCO warns oncology nurses of the risks of ivermectin and fenbendazole, urging proactive patient communication and monitoring ...
Following the landmark results of the RASolute 302 trial, Mary Larsen, MSN, RN, OCN, a clinical trials nurse at Memorial ...
The FDA approved the BESREMi Pen for polycythemia vera, offering a simplified self-administration option to improve patient adherence and care. PharmaEssentia USA Corporation has announced that the ...
Effective delegation within the research team is also vital. Licensed medical assistants (MAs) play a critical role by ...
The FDA approved Azurity’s Aprepitant Injectable Emulsion, a polysorbate-80-free, ready-to-use IV option for preventing chemotherapy-induced nausea. The FDA approved the BESREMi Pen for polycythemia ...
The core of this optimization strategy is the geriatric assessment. At Mount Sinai, Jakubowski noted that patients aged 65 and older — and in some cases, those 60 and older — receive a comprehensive ...
CIBMTR data shows manageable toxicity and outpatient potential for liso-cel in R/R MCL, emphasizing the vital role of nursing ...
Hughes discusses managing GI toxicities and the need for research regarding GLP-1 use among breast cancer patients and survivors. As the clinical use of GLP-1 receptor agonists continues to rise, ...
Oncology nurses can guide patients through the rationale and implications of this decision. Oncology nurses frequently address patient questions regarding unconventional or repurposed therapies, ...
FDA approves sacituzumab govitecan-hziy as monotherapy and with pembrolizumab for first-line treatment of advanced triple-negative breast cancer. On June 24, 2026, the Food and Drug Administration ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results